For Immediate ReleaseJanuary 31, 2022

Sumitomo Chemical Reports
Consolidated Financial Results
For the Nine Months Ended December 31, 2021
For the nine months ended December 31, 2021, the Sumitomo Chemical Group
reported consolidated sales revenue of ¥2,037.9 billion, an increase of ¥395.3 billion
year on year, core operating income* of ¥205.7 billion, operating income of ¥197.9billion, and net income attributable to owners of the parent of ¥133.7 billion, all higher
than the results from the same period of the previous year.
*Core operating income is a gain and loss concept, reflecting recurring earning
capacity, and deducts gains and losses incurred by non-recurring factors fromoperating income. It includes the share of profit from investments accounted for using
the equity method.
The financial results by business segment for the nine-month period are as follows:
Petrochemicals & Plastics
Market prices of petrochemical products, synthetic resins and synthetic fibers
increased due to a recovery in demand and an increase in raw material prices. Margins
also improved. Therefore, sales revenue increased by ¥216.6 billion, to ¥625.0 billion,
and core operating income recovered by ¥79.9 billion, to ¥52.0 billion, compared withthe same period of the previous year, when the shipment volumes decreased due tothe periodic shutdown maintenance for Rabigh Refining and Petrochemical Company,
our equity method investee, and due to the impact of the COVID-19 pandemic, mainly
on demand for automotive use.

Energy & Functional Materials
Shipments of separators for lithium-ion secondary batteries performed well. Market
prices for aluminum and for the metal raw materials for cathode materials increased,
resulting in higher selling prices. For the same period of the previous year, shipments
were lower, mainly for automotive use, due to the COVID-19 pandemic. As a result,sales revenue increased by ¥51.3 billion from the same period of the previous year, to¥226.7 billion. Core operating income increased by ¥3.0 billion from the same periodof the previous year, to ¥18.6 billion.
IT-related Chemicals
Shipments of processing materials for semiconductors (including high purity
chemicals and photoresists) increased, driven by growing demand for these items.
Shipments of materials for display applications increased in the face of stay-at-homedemand, and telework demand continued from the previous year. As a result, sales
revenue increased by ¥27.8 billion from the same period of the previous year, to ¥352.1
billion, and core operating income increased by ¥14.1 billion from the same period of
the previous year, to ¥46.0 billion.
Health & Crop Sciences
Shipments of crop protection products in North America, South America and India
stayed firm. Market prices of methionine (feed additives) increased from the same
period of the previous year. As a result, sales revenue increased by ¥48.5 billion fromthe same period of the previous year, to ¥331.0 billion. Core operating income
increased by ¥16.5 billion from the same period of the previous year, to ¥27.8 billion.



Pharmaceuticals
In North America, Orgovyx™ (therapeutic agent for advanced prostate cancer), which
was launched in the previous fiscal year, and Gemtesa® (therapeutic agent for
overactive bladder) and Myfembree® (therapeutic agent for uterine fibroids), both ofwhich commenced sales in the first quarter, as well as the recording of a lump-sum
upfront payment for the collaboration and license agreement for joint development
and commercialization, contributed to sales revenue. These more than offset negative
impacts, such as declines in sales of drugs such as Latuda® (atypical antipsychoticagent) and Brovana® (therapeutic agent for chronic obstructive pulmonary disease),
the latter of which saw its exclusive marketing period expire. On the other hand, inJapan, sales revenues were adversely affected by the National Health Insurance (NHI)
drug price revisions. As a result, sales revenue increased by ¥38.7 billion from thesame period of the previous year, to ¥456.3 billion. Core operating income decreasedby ¥12.3 billion from the previous year, to ¥62.5 billion, because selling, general andadministrative expenses increased significantly due to the start of full-scale marketing
activities by subsidiaries of Sumitovant Biopharma Limited, despite the increase ofsales revenue.
OthersIn addition to the above five segments, the Sumitomo Chemical Group supplies
electric power and steam, designs chemical plants and supervises the constructionof those facilities, provides transportation and warehousing, and conducts physicalproperty analysis and environmental analysis. Sales revenue of these businesses
increased by ¥12.3 billion from the same period of the previous year, to ¥46.9 billion,
and core operating income increased by ¥1.9 billion from the same period of theprevious year, to ¥12.1 billion.

Summary of Consolidated Results(1) Results of Operations:
Sales revenue
Core operating income(Share of profit of investments
accounted for using the equity method)
Operating income
Income before taxes
Net income
Net income attributable tonon-controlling interests
Net income attributable toowners of the parentNet income per 1,000 shares

Comprehensive income(9 Months ended
December 31, 2021
USD (Thousands)*1
Yen (Millions)
2,037,877
17,717,588
205,669
1,788,115
33,312 )(289,619 )9 Months ended
December 31, 2020 *2
Yen (Millions)
1,642,610
106,099((21,927) )197,923
209,539
155,665

1,720,770
1,821,761
1,353,373

115,772
92,26452,42222,002

191,288

32,194

133,663

1,162,085

20,228Yen
81,752

USD*1
711

Yen
12,372

Yen (Millions)
160,620

USD (Thousands)*1
1,396,453

Yen (Millions)
15,484As of December 31, 2021
USD (Thousands)*1
Yen (Millions)
4,229,439
36,771,335
1,606,842
13,970,110

As of March 31, 2021
Yen (Millions)
3,990,254
1,482,119

9 Months ended
December 31, 2021
USD (Thousands)*1
Yen (Millions)
99,019860,885(85,075)(739,654)
4,466
38,828
390,4393,394,531

9 Months ended
December 31, 2020 *2
Yen (Millions)273,426(159,933)
103,141404,0819 Months ended
December 31, 2021
USD (Thousands)*1
Yen (Millions)

9 Months ended
December 31, 2020 *2
Yen (Millions)䚷(2) Financial Position:
Total assets
Total equity(3) Cash Flows:
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations by䚷䚷䚷Business Segment:
Sales revenue
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersCore operating income
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

624,950
226,672
352,085
330,961456,26646,943
2,037,877

5,433,403
1,970,718
3,061,076
2,877,421
3,966,841
408,129
17,717,588

408,390
175,369
324,269
282,443
417,530
34,6091,642,610

51,997
18,62945,96827,80862,45912,147(13,339)
205,669

452,069
161,963399,652
241,767
543,027
105,608(115,971)
1,788,115(27,870)
15,58531,83911,29374,73910,286(9,773)106,099(Note)
䚷 *1䚷U.S. dollar amounts are translated from yen, for convenience only, at the rate ofࠉ¥115.02 = $1 prevailing on December 31, 2021.
䚷*2䚷Previous nine-months results were adjusted retrospectively because the temporary accounting treatment related
to business combinations was finalized.